Sharon Mates - 26 Aug 2024 Form 4 Insider Report for Intra-Cellular Therapies, Inc. (ITCI)

Role
Chairman and CEO, Director
Signature
/s/ John P. Condon, Attorney-in-fact
Issuer symbol
ITCI
Transactions as of
26 Aug 2024
Net transactions value
-$5,368,683
Form type
4
Filing time
28 Aug 2024, 18:00:57 UTC
Previous filing
23 Aug 2024
Next filing
30 Aug 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ITCI Common Stock Options Exercise $399,067 +22,713 +2.1% $17.57 1,093,042 26 Aug 2024 Direct
transaction ITCI Common Stock Sale $1,694,229 -22,713 -2.1% $74.59 1,070,329 26 Aug 2024 Direct F1, F2
transaction ITCI Common Stock Options Exercise $711,813 +40,513 +3.8% $17.57 1,110,842 27 Aug 2024 Direct
transaction ITCI Common Stock Sale $1,734,865 -23,657 -2.1% $73.33 1,087,185 27 Aug 2024 Direct F1, F3
transaction ITCI Common Stock Sale $1,246,191 -16,856 -1.6% $73.93 1,070,329 27 Aug 2024 Direct F1, F4
transaction ITCI Common Stock Options Exercise $574,521 +32,699 +3.1% $17.57 1,103,028 28 Aug 2024 Direct
transaction ITCI Common Stock Sale $2,361,113 -32,459 -2.9% $72.74 1,070,569 28 Aug 2024 Direct F1, F5
transaction ITCI Common Stock Sale $17,688 -240 -0.02% $73.70 1,070,329 28 Aug 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ITCI Stock Option (right to buy) Options Exercise $0 -22,713 -24% $0.000000 73,212 26 Aug 2024 Common Stock 22,713 $17.57 Direct F6
transaction ITCI Stock Option (right to buy) Options Exercise $0 -40,513 -55% $0.000000 32,699 27 Aug 2024 Common Stock 40,513 $17.57 Direct F6
transaction ITCI Stock Option (right to buy) Options Exercise $0 -32,699 -100% $0.000000 0 28 Aug 2024 Common Stock 32,699 $17.57 Direct F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 22, 2024. The shares sold were issued upon the exercise of stock options that expire on January 2, 2025.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $74.35 to $75.12, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $72.88 to $73.87, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above.
F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $73.88 to $74.39, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above.
F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $72.42 to $73.25, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above.
F6 This option was granted on January 2, 2015 with an exercise price of $17.57 per share and will expire on January 2, 2025. All shares underlying this option have vested.